Skip to main content

Latest news

Neuer Inhalt Free Registration

Gain full access to the latest clinical content available from Springer Nature

Breaking headlines, in-depth features, hot topic review articles, and 

the latest from major international conferences brought to you by

Editors' pick

10-11-2017 | Rheumatoid arthritis | ACR/ARHP 2017 | News

Promising results with upadacitinib in RA patients

Results of the SELECT-BEYOND trial suggest that the Janus kinase inhibitor upadacitinib may be a useful treatment option for patients with treatment-refractory rheumatoid arthritis.

Latest headlines

22-11-2017 | Axial spondyloarthritis | News

Predictors of biologic treatment failure in AxSpA patients identified

 It may be possible to identify patients with axial spondyloarthritis who are unlikely to respond to tumor necrosis factor inhibitor treatment using their baseline factors, researchers report.


Arthritis Care Res 2017; Advance online publication

21-11-2017 | Juvenile idiopathic arthritis | ACR/ARHP 2017 | News

News in brief

Tocilizumab promising in short and long term for severe JIA-associated uveitis

The anti-interleukin-6 receptor antibody tocilizumab improves ocular outcomes in the short and long term in patients with severe uveitis related to juvenile idiopathic arthritis, indicates research presented at the 2017 ACR/ARHP Annual Meeting in San Diego, California, USA.

20-11-2017 | Osteoarthritis | ACR/ARHP 2017 | News

Sprifermin shows potential as a disease-modifying OA treatment

Results of the phase II FORWARD trial suggest that sprifermin, an investigational recombinant human fibroblast growth factor, may prevent cartilage loss in patients with knee osteoarthritis, but its effect on pain and physical function remains unclear.

20-11-2017 | Gout | News

Regulatory update

FDA announces febuxostat safety alert

Click through to read more on this announcement

17-11-2017 | Juvenile idiopathic arthritis | ACR/ARHP 2017 | News

Online self-management program boosts JIA HRQoL

An internet-based educational tool developed by Canadian researchers helps adolescents with juvenile idiopathic arthritis to manage their disease and leads to improvements in their health-related quality of life relative to standard disease education.

15-11-2017 | Psoriatic arthritis | ACR/ARHP 2017 | News

News in brief

Extended benefits of ixekizumab treatment in patients with PsA

Results from the extension phase of the SPIRIT-P2 trial suggest that the benefits of treatment with ixekizumab are maintained for up to 1 year among patients with psoriatic arthritis.

In depth

10-10-2017 | Juvenile idiopathic arthritis | Feature | Article

Talking point: Are biologics over-used in the treatment of JIA?

Timothy Beukelman speaks to medwireNews about the differing viewpoints on whether biologic treatments are over-used for the treatment of children with juvenile idiopathic arthritis.

12-09-2017 | Rheumatoid arthritis | Feature | Article

At a glance: Trials evaluating baricitinib in RA

Our quick guide to the phase II and III trials of baricitinib for the treatment of rheumatoid arthritis. 

05-06-2017 | Rheumatoid arthritis | Feature | Article

JAK inhibitors: The next generation of drugs for treating rheumatoid arthritis?

medwireNews takes a look at the efficacy and safety profiles of JAK inhibitors for the treatment of rheumatoid arthritis, and addresses some common questions about their use.

image credits